Mr. Journo
Home Health And Fitness Renal Denervation Market Growth Factors, Opportunity, Segments, and Key Player’s Analysis
Health And Fitness

Renal Denervation Market Growth Factors, Opportunity, Segments, and Key Player’s Analysis

by Talib Hussain - 07 Sep 2022, Wednesday 309 Views Like (0)
Renal Denervation Market Growth Factors, Opportunity, Segments, and Key Player’s Analysis

Renal denervation market growth factors,

In treating uncontrolled or persistent hypertension, renal denervation devices play an important role in contemporary healthcare if hypertensive medicine is unsuccessful. Catheter-based minimally invasive therapy is used to treat hypertension. Renal denervation is the medical term for treating hypertension. The market is growing due to the rising incidence of hypertension and related long-term problems.

The market for renal denervation was worth $219.49 million in 2021 and is anticipated to grow to $4743.13 million by 2030, at a CAGR of 40.7% from 2021 to 2030.

The renal denervation market has grown due to changes in lifestyle that cause resistant hypertension and an increase in hypertension prevalence. Furthermore, technological advancements that have resulted in the development of alternative technologies for renal denervation systems, such as micro-infusion, have accelerated the growth of the renal denervation market. Furthermore, the prevalence of hypertension has increased significantly in recent years, causing fluctuations in blood pressure, but if it remains high for a large period of time, it may harm one's heart and cause health concerns. According to the World Health Organization, hypertension will affect approximately 1.28 billion people aged 30 to 79 by 2021. An increase in hypertension cases is expected to drive demand for renal denervation devices during the forecasted period.

The Centers for Disease Control and Prevention (CDC) reported that more than 360,000 Americans died in 2013 due to high blood pressure. The prevalence of hypertension has risen from 17,307 per 100,000 people in 1990 to 20,525 per 100,000 people in 2015. However, renal denervation therapy is effective in lowering blood pressure. As a result, the benefits of these therapies, such as permanent effect, reduced treatment time, and increased safety, drive market growth. Furthermore, advances in renal denervation devices are expected to drive the market.

Market restraining factor

One of the major factors limiting the demand for renal denervation is the risk of infection following surgery. Infections in the patient's body can result from any type of surgery that involves skin cuts, incisions, or other treatments.

The high cost of these techniques may hamper the global renal denervation market's growth.


Growing patient's preference for minimally invasive procedures

 A minimally invasive procedure is used to treat hypertension. An ultrasound-based renal denervation device sends an ultrasound inside the renal artery wall to disrupt nerve impulse transmission and lower blood pressure. This process improves efficiency, paving the way for the renal denervation market's future.

Segmentation analysis

  • By technology, the renal denervation market is divided into radiofrequency, ultrasound, and micro-infusion.

The radiofrequency segment held 75.15% of the market share in 2017. Radiofrequency is a one-time procedure that treats hypertension for at least two years, increasing market share.

The ultrasound segment will grow at the fastest CAGR because it overcomes the limitations of radiofrequency-based systems. Ultrasound energy with high-frequency sound waves ablates nerves without direct contact with tissues, reducing renal artery injuries.

  • Regionally, the market is segmented into Asia-Pacific, Europe, LAMEA, and North America.

Europe ruled the market for renal denervation in 2017 and is expected to maintain its dominance throughout the forecast period. It is mainly due to increased R&D activities aimed at developing efficient devices. An increase will also aid the region's growth in drug-resistant hypertension cases. Additionally, device approval in the European region is expected to boost the market growth.

The Asia Pacific (APAC) region is expected to grow the fastest during the forecast period due to an increase in diabetes, obesity, and other lifestyle diseases. Furthermore, the presence of a large target huge population in developing economies such as Japan and China is one of APAC's primary drivers of market growth.

Market share insights

Some of the companies in this market are:

  • Medtronic PLC
  • Cardiosonic, Inc.
  • Kona Medical, Inc.
  • Abbott Laboratories
  • Ablative Solutions, Inc.
  • Renal Dynamics
  • Mercator MedSystems, Inc.
  • ReCor Medical, Inc.
  • Boston Scientific Corp.
  • Symple Surgical, Inc. 

The size of the renal denervation market is expanding due to the increasing prevalence of treatment-resistant hypertension and hypertension due to increasing lifestyle changes. In addition, technological advances that have led to the development of alternative techniques for renal denervation systems, such as; B. Microinfusions, have driven the growth of the renal denervation market.